{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:13:17Z","timestamp":1789243997479,"version":"build-2803163510"},"reference-count":43,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["1R01CA267978"],"award-info":[{"award-number":["1R01CA267978"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: The protein kinases CLK and ROCK play key roles in cell growth and migration, respectively, and are potential anticancer targets. ROCK inhibitors have been approved by the FDA for various diseases and CLK inhibitors are currently being trialed in the clinic as anticancer agents. Compounds with polypharmacology are desired, especially in oncology, due to the potential for high efficacy as well as addressing resistance issues. In this report, we have identified and characterized novel, boron-containing dual CLK\/ROCK inhibitors with promising anticancer properties. Methods: A library of boronic acid-based CLK\/ROCKi was synthesized via Povarov\/Doebner-type multicomponent reactions. Kinase inhibition screening and cancer cell viability assays were performed to identify the hit compounds. To gain insights into the probable binding modes of the compounds to the kinases, docking studies were performed. Cell cycle analysis, qPCR and immunoblotting were carried out to further characterize the mode(s) of action of the lead candidates. Results: At 25 nM, the top compounds HSD1400 and HSD1791 inhibited CLK1 and 2 and ROCK2 at greater than 70%. While HSD1400 also inhibited CLK4, the C1 methylated analog HSD1791 did not inhibit CLK4. Antitumor effects of the top compounds were evaluated and dose\u2013response analysis indicated potent inhibition of renal cancer and leukemia cell growth. Immunoblotting results indicated that the top compounds induce DNA damage via upregulation of p-H2AX. Moreover, flow cytometry results demonstrated that the top compounds promote cell cycle arrest in the renal cancer cell line, Caki-1. qPCR and immunoblotting analysis upon HSD1791 dosing indicated suppression of cyclin D\/Rb oncogenic pathway upon compound treatment. Conclusions: Novel boronic acid-containing pyrazolo[4,3-f]quinoline-based dual CLK\/ROCK inhibitors were identified. The so-called \u201cmagic methylation\u201d design approach was used to tune CLK selectivity. Additionally, the findings demonstrate potent in vitro anticancer activity of the lead candidates against renal cancer and leukemia. This adds to the growing list of boron-containing compounds that display biological activities.<\/jats:p>","DOI":"10.3390\/ph17121660","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T04:15:03Z","timestamp":1733804103000},"page":"1660","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Boronic Acid-Containing 3H- pyrazolo[4,3-f]quinoline Compounds as Dual CLK\/ROCK Inhibitors with Anticancer Properties"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2705-7061","authenticated-orcid":false,"given":"Neetu","family":"Dayal","sequence":"first","affiliation":[{"name":"Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA"},{"name":"Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riddhi","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA"},{"name":"Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kofi Simpa","family":"Yeboah","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA"},{"name":"Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5349-2321","authenticated-orcid":false,"given":"Nickolas R.","family":"Brauer","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA"},{"name":"Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-9359","authenticated-orcid":false,"given":"Herman O.","family":"Sintim","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA"},{"name":"Purdue Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, USA"},{"name":"Purdue Institute for Cancer Research, Purdue University, 201 S. University Street, West Lafayette, IN 47907, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1039\/C3CS60197H","article-title":"Selection of boron reagents for Suzuki\u2013Miyaura coupling","volume":"43","author":"Lennox","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/acs.chemrev.5b00300","article-title":"Synthesis and Applications of Boronic Acid-Containing Polymers: From Materials to Medicine","volume":"116","author":"Brooks","year":"2016","journal-title":"Chem. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/adsc.202200204","article-title":"Uncovering the Potential of Boronic Acid and Derivatives as Radical Source in Photo(electro)chemical Reactions","volume":"364","author":"Pillitteri","year":"2022","journal-title":"Adv. Synth. Catal."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e202201249","DOI":"10.1002\/ejoc.202201249","article-title":"Boron Catalysis in the Transformation of Carboxylic Acids and Carboxylic Acid Derivatives","volume":"26","author":"Sawamura","year":"2023","journal-title":"Eur. J. Org. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1021\/jo4013942","article-title":"Boronic Esters in Asymmetric Synthesis","volume":"78","author":"Matteson","year":"2013","journal-title":"J. Org. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1039\/D4CY00034J","article-title":"Recent advances in Chan\u2013Lam coupling reaction","volume":"14","author":"Devi","year":"2024","journal-title":"Catal. Sci. Technol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1002\/hsr2.104","article-title":"Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice","volume":"2","author":"Hulin","year":"2019","journal-title":"Health Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","article-title":"Boron in drug design: Recent advances in the development of new therapeutic agents","volume":"179","author":"Fernandes","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Messner, K., Vuong, B., and Tranmer, G.K. (2022). The Boron Advantage: The Evolution and Diversification of Boron\u2019s Applications in Medicinal Chemistry. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030264"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13629","DOI":"10.1039\/D1CC05481C","article-title":"The modern role of boron as a \u2018magic element\u2019 in biomedical science: Chemistry perspective","volume":"57","author":"Chatterjee","year":"2021","journal-title":"Chem. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ejmech.2019.06.089","article-title":"Potently inhibiting cancer cell migration with novel 3H-pyrazolo[4,3-f]quinoline boronic acid ROCK inhibitors","volume":"180","author":"Dayal","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_12","first-page":"833","article-title":"ROCK1 promotes migration and invasion of non-small-cell lung cancer cells through the PTEN\/PI3K\/FAK pathway","volume":"55","author":"Hu","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.trecan.2022.12.001","article-title":"Preclinical to clinical utility of ROCK inhibitors in cancer","volume":"9","author":"Barcelo","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/med.21928","article-title":"An overview of cdc2-like kinase 1 (Clk1) inhibitors and their therapeutic indications","volume":"43","author":"ElHady","year":"2023","journal-title":"Med. Res. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e8289","DOI":"10.15252\/emmm.201708289","article-title":"Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability","volume":"10","author":"Iwai","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Shimizu, T., Yonemori, K., Koyama, T., Katsuya, Y., Sato, J., Fukuhara, N., Yokoyama, H., Iida, H., Ando, K., and Fukuhara, S. (2022). A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors. J. Clin. Oncol., 40.","DOI":"10.1200\/JCO.2022.40.16_suppl.3080"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Al-Kali, A., Saliba, A., Arana Yi, C.Y., Foran, J.M., Tanoue, Y., Yamamoto, M., Gullbo, J., and Garcia-Manero, G. (2023). Phase 1\/2 Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed\/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes. Blood, 142.","DOI":"10.1182\/blood-2023-173496"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.drup.2023.100929","article-title":"Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers","volume":"67","author":"Jin","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bonner, E.A., and Lee, S.C. (2023). Therapeutic Targeting of RNA Splicing in Cancer. Genes, 14.","DOI":"10.3390\/genes14071378"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e10288","DOI":"10.7554\/eLife.10288","article-title":"An extensive program of periodic alternative splicing linked to cell cycle progression","volume":"5","author":"Dominguez","year":"2016","journal-title":"Elife"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1351\/pac196409010049","article-title":"The structure of tetrodotoxin","volume":"9","author":"Woodward","year":"1964","journal-title":"Pure Appl. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10981","DOI":"10.1021\/acs.jmedchem.1c00330","article-title":"3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo","volume":"64","author":"Dayal","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Martin Moyano, P., Nemec, V., and Paruch, K. (2020). Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207549"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11451","DOI":"10.1038\/ncomms11451","article-title":"Clks 1, 2 and 4 prevent chromatin breakage by regulating the Aurora B-dependent abscission checkpoint","volume":"7","author":"Petsalaki","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Park, W.J., and Kim, M.J. (2023). A New Wave of Targeting \u2018Undruggable\u2019 Wnt Signaling for Cancer Therapy: Challenges and Opportunities. Cells, 12.","DOI":"10.3390\/cells12081110"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2019.09.009","article-title":"The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models","volume":"473","author":"Tam","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/cdd.2014.73","article-title":"Modulation of p53\u03b2 and p53\u03b3 expression by regulating the alternative splicing of TP53 gene modifies cellular response","volume":"21","author":"Marcel","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1101\/gad.247361.114","article-title":"Detained introns are a novel, widespread class of post-transcriptionally spliced introns","volume":"29","author":"Boutz","year":"2015","journal-title":"Genes. Dev."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Araki, S., Ohori, M., and Yugami, M. (2023). Targeting pre-mRNA splicing in cancers: Roles, inhibitors, and therapeutic opportunities. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1152087"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ghelli Luserna di Rora, A., Jandoubi, M., Martinelli, G., and Simonetti, G. (2023). Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon. Molecules, 28.","DOI":"10.3390\/molecules28031224"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Murai, A., Ebara, S., Sasaki, S., Ohashi, T., Miyazaki, T., Nomura, T., and Araki, S. (2020). Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0240718"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wu, H., Chen, Y., Li, B., Li, C., Guo, J., You, J., Hu, X., Kuang, D., Qi, S., and Liu, P. (2021). Targeting ROCK1\/2 blocks cell division and induces mitotic catastrophe in hepatocellular carcinoma. Biochem. Pharmacol., 184.","DOI":"10.1016\/j.bcp.2020.114353"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Araki, S., Dairiki, R., Nakayama, Y., Murai, A., Miyashita, R., Iwatani, M., Nomura, T., and Nakanishi, O. (2015). Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116929"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41419-022-05251-4","article-title":"Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation","volume":"13","author":"Marona","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2010.11.009","article-title":"Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing","volume":"18","author":"Fedorov","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3727\/096504020X15965357399750","article-title":"Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission","volume":"28","author":"Patel","year":"2021","journal-title":"Oncol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2019-130500","article-title":"SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models","volume":"134","author":"Chung","year":"2019","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1038\/onc.2013.533","article-title":"Hallmarks of alternative splicing in cancer","volume":"33","author":"Oltean","year":"2014","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrneph.2017.82","article-title":"Targeted therapies for renal cell carcinoma","volume":"13","author":"Posadas","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bioorg.2018.03.031","article-title":"3H-pyrazolo[4,3-f]quinoline haspin kinase inhibitors and anticancer properties","volume":"78","author":"Dayal","year":"2018","journal-title":"Bioorg. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1021\/acschembio.1c00342","article-title":"c-di-GMP Induces COX-2 Expression in Macrophages in a STING-Independent Manner","volume":"16","author":"Wang","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3748\/wjg.v8.i5.804","article-title":"Association of hTcf-4 gene expression and mutation with clinicopathological characteristics of hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2002","journal-title":"World J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1309\/R2BC-2H7T-7KB6-0YG8","article-title":"Analysis of cyclin D1 expression by quantitative real-time reverse transcription-polymerase chain reaction in the diagnosis of mantle cell lymphoma","volume":"117","author":"Peghini","year":"2002","journal-title":"Am. J. Clin. Pathol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1660\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:51:03Z","timestamp":1760115063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ph17121660"],"URL":"https:\/\/doi.org\/10.3390\/ph17121660","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}